Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain
Open Access
- 1 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 138 (6) , 1642-1657
Abstract
Oligomeric forms of alpha-synuclein are emerging as key mediators of pathogenesis in Parkinson’s disease. Our understanding of the exact contribution of alpha-synuclein oligomers to disease is limited by the lack of a technique for their specific detection. We describe a novel method, the alpha-synuclein proximity ligation assay, which specifically recognizes alpha-synuclein oligomers. In a blinded study with post-mortem brain tissue from patients with Parkinson’s disease (n = 8, age range 73–92 years, four males and four females) and age- and sex-matched controls (n = 8), we show that the alpha-synuclein proximity ligation assay reveals previously unrecognized pathology in the form of extensive diffuse deposition of alpha-synuclein oligomers. These oligomers are often localized, in the absence of Lewy bodies, to neuroanatomical regions mildly affected in Parkinson’s disease. Diffuse alpha-synuclein proximity ligation assay signal is significantly more abundant in patients compared to controls in regions including the cingulate cortex (1.6-fold increase) and the reticular formation of the medulla (6.5-fold increase). In addition, the alpha-synuclein proximity ligation assay labels very early perikaryal aggregates in morphologically intact neurons that may precede the development of classical Parkinson’s disease lesions, such as pale bodies or Lewy bodies. Furthermore, the alpha-synuclein proximity ligation assay preferentially detects early-stage, loosely compacted lesions such as pale bodies in patient tissue, whereas Lewy bodies, considered heavily compacted late lesions are only very exceptionally stained. The alpha-synuclein proximity ligation assay preferentially labels alpha-synuclein oligomers produced in vitro compared to monomers and fibrils, while stained oligomers in human brain display a distinct intermediate proteinase K resistance, suggesting the detection of a conformer that is different from both physiological, presynaptic alpha-synuclein (proteinase K-sensitive) and highly aggregated alpha-synuclein within Lewy bodies (proteinase K-resistant). These disease-associated conformers represent previously undetected Parkinson’s disease pathology uncovered by the alpha-synuclein proximity ligation assay.Keywords
This publication has 71 references indexed in Scilit:
- Direct Observation of the Interconversion of Normal and Toxic Forms of α-SynucleinCell, 2012
- α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregationNature, 2011
- The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementiaActa Neuropathologica, 2010
- Prion-like transmission of protein aggregates in neurodegenerative diseasesNature Reviews Molecular Cell Biology, 2010
- Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synucleinProceedings of the National Academy of Sciences, 2009
- Conditional Glycosylation in Eukaryotic Cells Using a Biocompatible Chemical Inducer of DimerizationJournal of the American Chemical Society, 2008
- Direct observation of individual endogenous protein complexes in situ by proximity ligationNature Methods, 2006
- The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementiaAnnals of Neurology, 2003
- Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseasesNature, 2002
- Vesicle Permeabilization by Protofibrillar α-Synuclein: Implications for the Pathogenesis and Treatment of Parkinson's DiseaseBiochemistry, 2001